According to the firm, biotech equities have tremendous upside potential and an “option-like structure,” particularly ... Libtayo, and Dupixent. With over a million patients treated globally ...
Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for atopic dermatitis, asthma, and more. It works to treat those conditions by blocking proteins that cause ...
Nucala (mepolizumab) and Dupixent (dupilumab) are brand-name subcutaneous injections. They’re both prescribed for asthma and chronic rhinosinusitis with nasal polyps. Each drug may also be ...
4don MSN
A study from Cornell researchers could enable a quantum leap forward in identifying and deciphering cancer-driving genetic ...
In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD ...
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...
Scientists have long struggled to target proteins that lack defined structure and are involved in cancer, neurodegenerative ...
Our skin and mucous membranes are protected by epithelial cells, which form a barrier that defends the body from the outside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback